John Talley Takes on Cancer with Euclises Pharmaceuticals
- Visitors
St. Louis' Euclises Pharmaceuticals, co-founded by renowned drug discoverer John Talley, aims to take on colorectal cancer, the third most common type of the disease in the U.S.
In the medical research and discovery industry, no foe is more varied or formidable than cancer. The fight against one of mankindβs deadliest diseases has innumerable fronts, from prevention to detection to treatment.
St. Louisβ Euclises Pharmaceuticals, co-founded by renowned drug discoverer John Talley,
aims to take on colorectal cancer, the third most common type of the disease in the U.S. While the impact of colorectal cancer is immense (Cancer.org estimated the expected death toll to reach nearly 50,000 in 2015), the solution Euclises is researching begins on the tiniest of scales.
βThereβs a particular molecular pathway thatβs really important to metastatic colorectal stage 4, to the pathophysiology of the disease,β says Talley, who serves as the companyβs chief scientific officer.
βIf you block this pathway, you can slow down tumor progression and metastasis. Thereβs a phenomenon called angiogenesis in which the blood vessels grow in to feed the tumor. This molecule is designed to block this phenomenon as well.β
Where It All Began
Talleyβs work on this new drug began with the framework of one of his greatest successes, Pfizerβs hugely popular arthritis medication Celebrex. Research on Celebrex led to an understanding of the COX-2 enzyme, which triggers inflammation.
Inhibiting COX-2 can slow and ideally stop the spread of cancer cells, though the dosage size of Celebrex required to effectively do so increased the risk of dangerous side effects. βWe think because this molecule is significantly more potent it stands a better chance of being successful in those settings,β Talley says.
βOver the years, thereβs been a considerably greater understanding of the role of COX-2 in different disease states, and most particularly, in development and progression of epithelial cancers (cancers of the colon, pancreas and lungs).β
New drug discovery is where Talley built his reputation, one that is reinforced by eight of his co-invented drugs reaching market to the tune of $40 billion in sales annually. Drug discovery and development is an expensive endeavor, but money follows success, making Euclises fundraising rounds a bit easier.
βBecause Iβve had the success that Iβve had, thereβs a level of credibility that someone who hasnβt had these successes just doesnβt have,β Talley admits.
βBut I think some investors think oncology is a really tough area. Thereβs no doubt about that, but we also think this molecule stands a really good chance of having a real impact on lives.β
From Personal To Professional
That impact is personal for Talley, whose experience with colorectal cancer left a lasting impression that fuels his work.
βItβs a disease that affects quite a lot of people. It killed my dad so I saw first-hand how devastating it is,β he says. βThe treatments are fairly draconian. Typically thereβs surgery, and then thereβs a standard protocol that really hasnβt changed a whole lot in quite a while.β
The new drug would be layered in with existing treatments, aiming to slow the growth of cancer cells in order to extend both the duration and the quality of life.
What’s Next
For Euclises, the discovery stage of research is done. Talley and his team have identified their lead molecule and are doing pre-clinical development; which are the procedures outlined by the FDA to file an investigational new drug application.
The company hopes to begin in human trials at some point next year. That step, while exciting, comes with significant financial hurdles.
βThatβs a pretty big step for any company, but particularly a young one like ourselves. The question then becomes, βdo you have sufficient funds to get things into the clinic with the funds you have at the moment?ββ Talley asks.
βItβs going to take a lot of money to get where we want to go.β